Quality-of-life effects of prostate-specific antigen screening.
about
Screening for prostate cancerMolecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancerScreening Coverage Needed to Reduce Mortality from Prostate Cancer: A Living Systematic ReviewOverdiagnosis and overtreatment of prostate cancerProstate-specific kallikrein-related peptidases and their relation to prostate cancer biology and detection. Established relevance and emerging rolesScreening guidelines for non-AIDS defining cancers in HIV-infected individualsActive surveillance for prostate cancer: current evidence and contemporary state of practiceProstate cancer screening in Brazil: should it be done or not?A Review of Experimental and Off-Label Therapies for Clostridium difficile InfectionQuantifying Gleason scores with photoacoustic spectral analysis: feasibility study with human tissues.A reference set of health utilities for long-term survivors of prostate cancer: population-based data from Ontario, Canada.Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data.[The parameter "relative survival": Analysis of regional cancer registry data for prostate cancer].Prostate cancer screening: a complicated puzzle, explanation neededComparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trials.Design and preliminary recruitment results of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP)Nanoparticle Probes for the Detection of Cancer Biomarkers, Cells, and Tissues by FluorescenceBenefits and harms of prostate cancer screening - predictions of the ONCOTYROL prostate cancer outcome and policy model.Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task ForceScreening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits.Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms.Prostate-specific antigen screening in prostate cancer: perspectives on the evidencePotential clinical utility of ultrasensitive circulating tumor DNA detection with CAPP-Seq.Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen.Effects of surgeon variability on oncologic and functional outcomes in a population-based settingWhat do the screening trials really tell us and where do we go from here?Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, CanadaA snapshot of cancer in Chile: analytical frameworks for developing a cancer policyPROMIS--Prostate MR imaging study: A paired validating cohort study evaluating the role of multi-parametric MRI in men with clinical suspicion of prostate cancer.Ethnicity and prostate cancer: the way to solve the screening problem?TMPRSS2:ERG gene aberrations may provide insight into pT stage in prostate cancer.The role of targeted focal therapy in the management of low-risk prostate cancer: update on current challenges.Mode of prostate cancer detection is associated with the psychological wellbeing of survivors: results from the PiCTure study.Treatment of local-regional prostate cancer detected by PSA screening: benefits and harms according to prognostic factorsDivorcing diagnosis from treatment: contemporary management of low-risk prostate cancer.Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment StrategiesThe Effect of Start and Stop Age at Screening on the Risk of Being Diagnosed with Prostate Cancer.Absolute Effect of Prostate Cancer Screening: Balance of Benefits and Harms by Center within the European Randomized Study of Prostate Cancer Screening.Mutational load of the mitochondrial genome predicts pathological features and biochemical recurrence in prostate cancer.
P2860
Q24201690-D876E09B-3EF1-43BC-BB21-F9D71C84F55BQ26739708-BDBDF8AA-69DE-4ECE-906A-44F0809CDDC3Q26748873-8B6A4C5C-77BD-4F42-A565-8BAAD29DEEDDQ26859596-37D5450C-D2D0-4D52-B1EF-AB558375FB04Q26865810-4D79EF00-CA8B-4B32-A123-8C26D57EBCDCQ27021899-F2C40880-7FD2-48D2-9AC0-F89619C5C32CQ28066534-382C5A3E-5E78-461F-83B4-9F0A18CB620CQ28068688-3AE81232-2496-4076-A69F-57B85750AE39Q30240264-0EB9508C-F68F-4F4B-91E6-60306ACE1655Q30395328-6280CA8D-4D20-4BC7-8B91-5CD5A76B17CAQ30613075-D51C356A-31B9-4674-8654-7365806A7E39Q30878080-4915609F-24A5-4CFE-BFE2-80A0CBF0167EQ30992920-6B401B63-7E34-4AA7-BEC9-AD932587C5BDQ33356114-89E8885E-7EC5-4AFC-974B-B9F34BCFF1D1Q33651094-EE323748-D489-4E46-B310-368B4F679E22Q33750148-99629445-7DFF-45BA-8FE5-845E195A5D73Q33759991-B2B1BB82-8AA6-4957-B704-7751375B7DA5Q33836709-9A9059F1-A054-43A2-A475-081177E7BBD5Q33978331-5C85B2B1-077C-4C55-A8D1-DCD097FA5732Q34041688-56668A3A-FDA5-4FC7-AFC7-56EA02DD29EBQ34159375-8146E9BB-CACC-45D2-A204-38B4E185DCFFQ34326169-6825F4E3-8CC4-42AE-89E1-CF6FF3DDA69EQ34354430-6A4A4C52-11F7-49F7-B4C8-1582AED51D57Q34467274-D0003DF0-A9B6-41D6-B944-ED8C79FCB949Q35089983-9B36C2D4-213C-4704-998A-099452F503CCQ35112495-824509A6-7A57-405C-9C37-E1574696B411Q35234770-66CEFAAF-6B04-4863-8E41-86A5D81C0BE0Q35541638-C6361204-F69B-4194-ABF2-588E9EEAB058Q35562601-47E6825A-81DB-4E26-8EF2-9E0C47078361Q35700730-A3AE1009-7D76-4CA2-9CB7-4BE126DBDDC8Q35736485-CEC86765-094C-4719-B3EB-AAB71A3B8389Q36067872-3A1653A3-2788-4623-8C04-803B3AD04DA8Q36546399-CA1CE3BA-D02A-41F7-895F-4344CD8F75EFQ36723934-696730E6-C358-4854-812E-2843571E8909Q36896116-AF5ADBFF-9310-46AB-9A5C-2DDAA3FE9DE5Q37025434-FA687C7A-F162-45A3-A35D-B4CCC2C61607Q37095655-2ED396E6-F03B-4BE8-B2F5-235A0A12D58EQ37103771-AF9C4E58-056B-4B76-BBFE-1245457DBB29Q37109441-C3CB10B9-6411-4AEE-AAF8-517DA229CBB7Q37538185-77F37358-202D-4856-AF6C-8A0E5B067603
P2860
Quality-of-life effects of prostate-specific antigen screening.
description
2012 nî lūn-bûn
@nan
2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Quality-of-life effects of prostate-specific antigen screening.
@ast
Quality-of-life effects of prostate-specific antigen screening.
@en
Quality-of-life effects of prostate-specific antigen screening.
@nl
type
label
Quality-of-life effects of prostate-specific antigen screening.
@ast
Quality-of-life effects of prostate-specific antigen screening.
@en
Quality-of-life effects of prostate-specific antigen screening.
@nl
prefLabel
Quality-of-life effects of prostate-specific antigen screening.
@ast
Quality-of-life effects of prostate-specific antigen screening.
@en
Quality-of-life effects of prostate-specific antigen screening.
@nl
P2093
P2860
P50
P356
P1476
Quality-of-life effects of prostate-specific antigen screening
@en
P2093
Alvaro Páez
Chris H Bangma
Elisabeth M Wever
Eveline A M Heijnsdijk
Fritz H Schröder
Gerrit Draisma
Harry J de Koning
Ida J Korfage
Jonas Hugosson
Maciej Kwiatkowski
P2860
P304
P356
10.1056/NEJMOA1201637
P407
P577
2012-08-01T00:00:00Z